Abstract:BACKGROUND:Adenosine, derived from the degradation of ATP via ectonucleotidases CD39 and CD73, is a critical immunosuppressive metabolite in the hypoxic microenvironment of tumor tissue. Adenosine signaling via A2aR can inhibit the antitumor immune response of CD8+ T cells. CD39 and CD73 high-expressing Tregs play a critical role in tumor immune evasion of gastric cancer (GC). The present study investigated the underlying mechanism by which Tregs suppress antitumor immune responses in GC. MATERIALS AND METHODS:Fifty-two GC samples were collected, and the frequency of FoxP3+ Tregs and CD8+ T cells and density ratios of A2aR+/CD8+ T cells, CD39+/FoxP3+ Tregs, and CD73+/FoxP3+ Tregs in GC were assessed with multiplex immunofluorescence. The expression of FoxP3 and A2aR in GC tissues was also detected by the immunoblotting assay. We next investigated the relationship between density of FoxP3+ Tregs, ratio of A2aR+/CD8+ T cells, and clinicopathological parameters. At the same time, Tregs and CD8+ T cells were isolated from peripheral blood of five GC patients, and the antagonists of CD39 and CD73 were used to assess the ability of Tregs to decompose ATP into adenosine. In addition, we cocultured CD8+ T cells and Tregs with antagonists of A2aR and A2bR in order to examine the alterations in immune function of CD8+ T cells. RESULTS:The density of both FoxP3+ Tregs and A2aR+/CD8+ T cells was higher in GC tissue compared to peritumoral normal tissue and significantly correlated with the TNM stage, lymph node metastasis, and distant metastasis of GC. The process of Treg hydrolysis of ATP into adenosine was blocked by the antagonists of CD39 and CD73. In addition, Tregs could induce apoptosis and inhibit proliferation of CD8+ T cells, while this effect could be obviously reduced by applying the antagonist of A2aR or A2aR+A2bR. Moreover, IFN-γ, TNF-α, and perforin generated by CD8+ T cells could also be inhibited through the adenosine A2aR pathway. CONCLUSIONS:The FoxP3+ Tregs and A2aR+/CD8+ T cells were excessively infiltrated in GC tissue. Tregs from GC can decompose ATP to adenosine and in turn induce apoptosis and inhibit the proliferation of CD8+ T cells through the A2aR pathway, further leading to immune escape of GC.

Adenosine Signaling: Next Checkpoint for Gastric Cancer Immunotherapy?

Adenosine Signaling: Optimal Target for Gastric Cancer Immunotherapy

The inhibitory effect of adenosine on tumor adaptive immunity and intervention strategies

Targeting Adenosine Receptor Signaling in Cancer Immunotherapy

Targeting adenosine for cancer immunotherapy

The adenosine pathway in immuno-oncology

CD39/CD73/A2AR pathway and cancer immunotherapy

Adenosine-A2A Receptor Pathway in Cancer Immunotherapy

Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function

Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application

Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer

AB928, a Dual Antagonist of the A2aR and A2bR Adenosine Receptors, Leads to Greater Immune Activation and Reduced Tumor Growth when Combined with Chemotherapy

Adenosine Interaction with Adenosine Receptor A2a Promotes Gastric Cancer Metastasis by Enhancing PI3K-AKT-mTOR Signaling

Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity

Adenosine A2A Receptor Antagonists for Cancer Immunotherapy

Chelerythrine and Chelidonine Decrease Extracellular Adenosine Improving Cd8 + T Anti-Tumor Immunity

Targeting immunosuppressive adenosine in cancer

Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future

Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors

The Adenosinergic Pathway in Non-Small Cell Lung Cancer

Adenosine Generated by Regulatory T Cells Induces CD8+ T Cell Exhaustion in Gastric Cancer Through A2aR Pathway.